Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid
leukemia (CML). Although experience is too limited to permit evidence-based evaluation of …

The European Group for Blood and Marrow Transplantation (EBMT) risk score provides a
simple tool to assess instantly chances and risks of hematopoietic SCT (HSCT) for an …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Background Transplantation of blood or bone-marrow stem cells is the treatment of choice
for selected patients with chronic myeloid leukaemia (CML). Transplantation is used with …

Background A complete remission is essential for prolonging survival in patients with acute
myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the …

Acute graft‐versus‐host disease (GVHD) severity is graded by pattern of organ involvement
and clinical performance status using a system introduced by Glucksberg and colleagues 21 …

Background Graft-versus-host disease (GVHD) can be a major complication of allogeneic
bone marrow transplantation even when the donor and recipient are siblings and share …

Background Autologous hematopoietic stem cell transplantation has been used since 1996
for the treatment of severe autoimmune diseases refractory to approved therapies. We …